

# 2020 Cancer Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

<https://marketpublishers.com/r/20DC2A1DCA7BEN.html>

Date: February 2020

Pages: 132

Price: US\$ 1,999.00 (Single User License)

ID: 20DC2A1DCA7BEN

## Abstracts

The 2020 Cancer Pain pipeline report presents a comprehensive overview of the research and development of Cancer Pain drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, 16 drugs in pre-clinical phase, three drugs in Phase 1, eight drugs in Phase 2, five drugs in Phase 3 and one drug in Pre-registration phase

As of February 2020, the Cancer Pain pipeline remains robust with 35 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cancer Pain treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha 2 adrenergic receptor agonists; AMPA receptor agonists; CACNA2D1 (Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1) protein modulators; Cannabinoid receptor agonists; Chemokine CXCL13 inhibitors; Cyclooxygenase inhibitors; Dual ENKephalinase Inhibitor (DENKI); Fibroblast growth factor inhibitors; lipoprotein receptor-related protein (LRP-1); Mas receptor agonist; Matrix metalloproteinase 2 inhibitors; Matrix metalloproteinase 9 inhibitors; Mu opiate receptor agonist; mu opioid receptor agonist; multiple cathepsins inhibitor; Nav1.7 blocker; Nerve growth factor (NGF) inhibitor; NMDA receptor antagonist; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Sodium channel antagonists; Src, Fyn and Abl protein tyrosine kinases inhibitors; TRPV1 receptor agonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cancer Pain drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

## **PUBLISHER EXPERTISE**

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

## **SCOPE:**

The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cancer Pain development

Cancer Pain pipeline compounds and molecules under study by both large scale and small companies are included in the report

Cancer Pain pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered

Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered

Further, orphan drug status, fast track designation, different grants awarded and special status for Cancer Pain pipeline candidates included

Business overview and snapshot of all companies involved in Cancer Pain pipeline are included

Latest market and pipeline developments are provided in the report

Cancer Pain pipeline companies included in the report are- Alexza Pharmaceuticals Inc, AngioChem Inc, Aoxing Pharmaceutical Company Inc, Aphios Corp, Aquilus Pharmaceuticals Inc, AstraZeneca Plc, ChironWells GmbH, Concentric Analgesics Inc, Daewoong Pharmaceutical Co Ltd, Dompe Farmaceutici SpA, Fujimoto Pharmaceutical Corp, Hisamitsu Pharmaceutical Co Inc, Immupharma Plc, Intec Pharma Ltd, Klaria Pharma Holding AB, Komipharm International Co Ltd, Medlab Clinical Ltd, Mundipharma International Ltd, Nanomerics Ltd, Neurocentrx Pharma Ltd, Nippon Zoki Pharmaceutical Co Ltd, Oblique Therapeutics AB, Orion Corp, Pfizer Inc, Pharmaleads SA, ProNeurogen Inc, Recordati SpA, Ribomic Inc, Sedor Pharmaceuticals LLC, Sorrento Therapeutics Inc, Tetra Bio-Pharma Inc, Virobay Inc, WEX Pharmaceuticals Inc, Winston Pharmaceuticals Inc

Cancer Pain pipeline drugs profiled in the report include- fentanyl (AZ-003), ANG2002, tilidine, APH-0802 (dronabinol), AQU-118, AZD 8797, saracatinib difumarate, HS198, CA-051, DWP17061, gabapentin, RBM-004, RBM-007, HP-3150 (Diclofenac sodium), lpp-102199, cannabidiol, KL-00406, PAX-1, Cannabis, Buprenorphine transdermal, NM127, ketamine, tramadol, TRPV1 inhibitor for Cancer Pain, dexmedetomidine hydrochloride, tanezumab (PF-04383119), PL37, PNA5, methadone hydrochloride, meloxicam, resiniferatoxin, PPP001, VBY-825, Tetrodotoxin, zucapsaicin

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. EXECUTIVE SUMMARY

- 2.1 Report Scope and Research Methodology
- 2.2 Introduction to Cancer Pain Condition
- 2.3 Cancer Pain Pipeline Snapshot, 2020
- 2.4 Companies investing in Cancer Pain pipeline therapeutics
- 2.5 Phase wise Cancer Pain Pipeline Candidates
- 2.6 Most Researched Mechanism of Action of Cancer Pain Pipeline Products
- 2.7 Route of Administration of Cancer Pain Pipeline Drugs

### 3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

- 3.1 Alexza Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.2 AngioChem Inc Overview, Contacts and ASD Pipeline Drugs
- 3.3 Aoxing Pharmaceutical Company Inc Overview, Contacts and ASD Pipeline Drugs
- 3.4 Aphios Corp Overview, Contacts and ASD Pipeline Drugs
- 3.5 Aquilus Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.6 AstraZeneca Plc Overview, Contacts and ASD Pipeline Drugs
- 3.7 ChironWells GmbH Overview, Contacts and ASD Pipeline Drugs
- 3.8 Concentric Analgesics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.9 Daewoong Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.10 Dompe Farmaceutici SpA Overview, Contacts and ASD Pipeline Drugs
- 3.11 Fujimoto Pharmaceutical Corp Overview, Contacts and ASD Pipeline Drugs
- 3.12 Hisamitsu Pharmaceutical Co Inc Overview, Contacts and ASD Pipeline Drugs
- 3.13 Immupharma Plc Overview, Contacts and ASD Pipeline Drugs
- 3.14 Intec Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.15 Klaria Pharma Holding AB Overview, Contacts and ASD Pipeline Drugs
- 3.16 Komipharm International Co Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.17 Medlab Clinical Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.18 Mundipharma International Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.19 Nanomerics Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.20 Neurocentrx Pharma Ltd Overview, Contacts and ASD Pipeline Drugs

- 3.21 Nippon Zoki Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.22 Oblique Therapeutics AB Overview, Contacts and ASD Pipeline Drugs
- 3.23 Orion Corp Overview, Contacts and ASD Pipeline Drugs
- 3.24 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
- 3.25 Pharmaleads SA Overview, Contacts and ASD Pipeline Drugs
- 3.26 ProNeurogen Inc Overview, Contacts and ASD Pipeline Drugs
- 3.27 Recordati SpA Overview, Contacts and ASD Pipeline Drugs
- 3.28 Ribomic Inc Overview, Contacts and ASD Pipeline Drugs
- 3.29 Sedor Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
- 3.30 Sorrento Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.31 Tetra Bio-Pharma Inc Overview, Contacts and ASD Pipeline Drugs
- 3.32 Virobay Inc Overview, Contacts and ASD Pipeline Drugs
- 3.33 WEX Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.34 Winston Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

#### **4. ACTIVE PIPELINE DRUG DETAILS, 2020**

- 4.1 fentanyl (AZ-003) Drug Details
  - 4.1.1 fentanyl (AZ-003) Current Status
  - 4.1.2 fentanyl (AZ-003) Drug Overview
  - 4.1.3 fentanyl (AZ-003) Mechanism of Action
  - 4.1.4 fentanyl (AZ-003) Licensing/Collaboration Companies
  - 4.1.5 fentanyl (AZ-003) Clinical Trials
- 4.2 ANG2002 Drug Details
  - 4.2.1 ANG2002 Current Status
  - 4.2.2 ANG2002 Drug Overview
  - 4.2.3 ANG2002 Mechanism of Action
  - 4.2.4 ANG2002 Licensing/Collaboration Companies
  - 4.2.5 ANG2002 Clinical Trials
- 4.3 tilidine Drug Details
  - 4.3.1 tilidine Current Status
  - 4.3.2 tilidine Drug Overview
  - 4.3.3 tilidine Mechanism of Action
  - 4.3.4 tilidine Licensing/Collaboration Companies
  - 4.3.5 tilidine Clinical Trials
- 4.4 APH-0802 (dronabinol) Drug Details
  - 4.4.1 APH-0802 (dronabinol) Current Status
  - 4.4.2 APH-0802 (dronabinol) Drug Overview
  - 4.4.3 APH-0802 (dronabinol) Mechanism of Action

- 4.4.4 APH-0802 (dronabinol) Licensing/Collaboration Companies
- 4.4.5 APH-0802 (dronabinol) Clinical Trials
- 4.5 AQU-118 Drug Details
  - 4.5.1 AQU-118 Current Status
  - 4.5.2 AQU-118 Drug Overview
  - 4.5.3 AQU-118 Mechanism of Action
  - 4.5.4 AQU-118 Licensing/Collaboration Companies
  - 4.5.5 AQU-118 Clinical Trials
- 4.6 AZD 8797 Drug Details
  - 4.6.1 AZD 8797 Current Status
  - 4.6.2 AZD 8797 Drug Overview
  - 4.6.3 AZD 8797 Mechanism of Action
  - 4.6.4 AZD 8797 Licensing/Collaboration Companies
  - 4.6.5 AZD 8797 Clinical Trials
- 4.7 saracatinib difumarate Drug Details
  - 4.7.1 saracatinib difumarate Current Status
  - 4.7.2 saracatinib difumarate Drug Overview
  - 4.7.3 saracatinib difumarate Mechanism of Action
  - 4.7.4 saracatinib difumarate Licensing/Collaboration Companies
  - 4.7.5 saracatinib difumarate Clinical Trials
- 4.8 HS198 Drug Details
  - 4.8.1 HS198 Current Status
  - 4.8.2 HS198 Drug Overview
  - 4.8.3 HS198 Mechanism of Action
  - 4.8.4 HS198 Licensing/Collaboration Companies
  - 4.8.5 HS198 Clinical Trials
- 4.9 CA-051 Drug Details
  - 4.9.1 CA-051 Current Status
  - 4.9.2 CA-051 Drug Overview
  - 4.9.3 CA-051 Mechanism of Action
  - 4.9.4 CA-051 Licensing/Collaboration Companies
  - 4.9.5 CA-051 Clinical Trials
- 4.10 DWP17061 Drug Details
  - 4.10.1 DWP17061 Current Status
  - 4.10.2 DWP17061 Drug Overview
  - 4.10.3 DWP17061 Mechanism of Action
  - 4.10.4 DWP17061 Licensing/Collaboration Companies
  - 4.10.5 DWP17061 Clinical Trials
- 4.11 gabapentin Drug Details

- 4.11.1 gabapentin Current Status
- 4.11.2 gabapentin Drug Overview
- 4.11.3 gabapentin Mechanism of Action
- 4.11.4 gabapentin Licensing/Collaboration Companies
- 4.11.5 gabapentin Clinical Trials
- 4.12 RBM-004 Drug Details
  - 4.12.1 RBM-004 Current Status
  - 4.12.2 RBM-004 Drug Overview
  - 4.12.3 RBM-004 Mechanism of Action
  - 4.12.4 RBM-004 Licensing/Collaboration Companies
  - 4.12.5 RBM-004 Clinical Trials
- 4.13 RBM-007 Drug Details
  - 4.13.1 RBM-007 Current Status
  - 4.13.2 RBM-007 Drug Overview
  - 4.13.3 RBM-007 Mechanism of Action
  - 4.13.4 RBM-007 Licensing/Collaboration Companies
  - 4.13.5 RBM-007 Clinical Trials
- 4.14 HP-3150 (Diclofenac sodium) Drug Details
  - 4.14.1 HP-3150 (Diclofenac sodium) Current Status
  - 4.14.2 HP-3150 (Diclofenac sodium) Drug Overview
  - 4.14.3 HP-3150 (Diclofenac sodium) Mechanism of Action
  - 4.14.4 HP-3150 (Diclofenac sodium) Licensing/Collaboration Companies
  - 4.14.5 HP-3150 (Diclofenac sodium) Clinical Trials
- 4.15 Ipp-102199 Drug Details
  - 4.15.1 Ipp-102199 Current Status
  - 4.15.2 Ipp-102199 Drug Overview
  - 4.15.3 Ipp-102199 Mechanism of Action
  - 4.15.4 Ipp-102199 Licensing/Collaboration Companies
  - 4.15.5 Ipp-102199 Clinical Trials
- 4.16 cannabidiol Drug Details
  - 4.16.1 cannabidiol Current Status
  - 4.16.2 cannabidiol Drug Overview
  - 4.16.3 cannabidiol Mechanism of Action
  - 4.16.4 cannabidiol Licensing/Collaboration Companies
  - 4.16.5 cannabidiol Clinical Trials
- 4.17 KL-00406 Drug Details
  - 4.17.1 KL-00406 Current Status
  - 4.17.2 KL-00406 Drug Overview
  - 4.17.3 KL-00406 Mechanism of Action

- 4.17.4 KL-00406 Licensing/Collaboration Companies
- 4.17.5 KL-00406 Clinical Trials
- 4.18 PAX-1 Drug Details
  - 4.18.1 PAX-1 Current Status
  - 4.18.2 PAX-1 Drug Overview
  - 4.18.3 PAX-1 Mechanism of Action
  - 4.18.4 PAX-1 Licensing/Collaboration Companies
  - 4.18.5 PAX-1 Clinical Trials
- 4.19 Cannabis Drug Details
  - 4.19.1 Cannabis Current Status
  - 4.19.2 Cannabis Drug Overview
  - 4.19.3 Cannabis Mechanism of Action
  - 4.19.4 Cannabis Licensing/Collaboration Companies
  - 4.19.5 Cannabis Clinical Trials
- 4.20 Buprenorphine transdermal Drug Details
  - 4.20.1 Buprenorphine transdermal Current Status
  - 4.20.2 Buprenorphine transdermal Drug Overview
  - 4.20.3 Buprenorphine transdermal Mechanism of Action
  - 4.20.4 Buprenorphine transdermal Licensing/Collaboration Companies
  - 4.20.5 Buprenorphine transdermal Clinical Trials
- 4.21 NM127 Drug Details
  - 4.21.1 NM127 Current Status
  - 4.21.2 NM127 Drug Overview
  - 4.21.3 NM127 Mechanism of Action
  - 4.21.4 NM127 Licensing/Collaboration Companies
  - 4.21.5 NM127 Clinical Trials
- 4.22 ketamine Drug Details
  - 4.22.1 ketamine Current Status
  - 4.22.2 ketamine Drug Overview
  - 4.22.3 ketamine Mechanism of Action
  - 4.22.4 ketamine Licensing/Collaboration Companies
  - 4.22.5 ketamine Clinical Trials
- 4.23 tramadol Drug Details
  - 4.23.1 tramadol Current Status
  - 4.23.2 tramadol Drug Overview
  - 4.23.3 tramadol Mechanism of Action
  - 4.23.4 tramadol Licensing/Collaboration Companies
  - 4.23.5 tramadol Clinical Trials
- 4.24 TRPV1 inhibitor for Cancer Pain Drug Details



- 4.24.1 TRPV1 inhibitor for Cancer Pain Current Status
- 4.24.2 TRPV1 inhibitor for Cancer Pain Drug Overview
- 4.24.3 TRPV1 inhibitor for Cancer Pain Mechanism of Action
- 4.24.4 TRPV1 inhibitor for Cancer Pain Licensing/Collaboration Companies
- 4.24.5 TRPV1 inhibitor for Cancer Pain Clinical Trials
- 4.25 dexmedetomidine hydrochloride Drug Details
  - 4.25.1 dexmedetomidine hydrochloride Current Status
  - 4.25.2 dexmedetomidine hydrochloride Drug Overview
  - 4.25.3 dexmedetomidine hydrochloride Mechanism of Action
  - 4.25.4 dexmedetomidine hydrochloride Licensing/Collaboration Companies
  - 4.25.5 dexmedetomidine hydrochloride Clinical Trials
- 4.26 tanezumab (PF-04383119) Drug Details
  - 4.26.1 tanezumab (PF-04383119) Current Status
  - 4.26.2 tanezumab (PF-04383119) Drug Overview
  - 4.26.3 tanezumab (PF-04383119) Mechanism of Action
  - 4.26.4 tanezumab (PF-04383119) Licensing/Collaboration Companies
  - 4.26.5 tanezumab (PF-04383119) Clinical Trials
- 4.27 PL37 Drug Details
  - 4.27.1 PL37 Current Status
  - 4.27.2 PL37 Drug Overview
  - 4.27.3 PL37 Mechanism of Action
  - 4.27.4 PL37 Licensing/Collaboration Companies
  - 4.27.5 PL37 Clinical Trials
- 4.28 PNA5 Drug Details
  - 4.28.1 PNA5 Current Status
  - 4.28.2 PNA5 Drug Overview
  - 4.28.3 PNA5 Mechanism of Action
  - 4.28.4 PNA5 Licensing/Collaboration Companies
  - 4.28.5 PNA5 Clinical Trials
- 4.29 methadone hydrochloride Drug Details
  - 4.29.1 methadone hydrochloride Current Status
  - 4.29.2 methadone hydrochloride Drug Overview
  - 4.29.3 methadone hydrochloride Mechanism of Action
  - 4.29.4 methadone hydrochloride Licensing/Collaboration Companies
  - 4.29.5 methadone hydrochloride Clinical Trials
- 4.30 meloxicam Drug Details
  - 4.30.1 meloxicam Current Status
  - 4.30.2 meloxicam Drug Overview
  - 4.30.3 meloxicam Mechanism of Action

- 4.30.4 meloxicam Licensing/Collaboration Companies
- 4.30.5 meloxicam Clinical Trials
- 4.31 resiniferatoxin Drug Details
  - 4.31.1 resiniferatoxin Current Status
  - 4.31.2 resiniferatoxin Drug Overview
  - 4.31.3 resiniferatoxin Mechanism of Action
  - 4.31.4 resiniferatoxin Licensing/Collaboration Companies
  - 4.31.5 resiniferatoxin Clinical Trials
- 4.32 PPP001 Drug Details
  - 4.32.1 PPP001 Current Status
  - 4.32.2 PPP001 Drug Overview
  - 4.32.3 PPP001 Mechanism of Action
  - 4.32.4 PPP001 Licensing/Collaboration Companies
  - 4.32.5 PPP001 Clinical Trials
- 4.33 VBY-825 Drug Details
  - 4.33.1 VBY-825 Current Status
  - 4.33.2 VBY-825 Drug Overview
  - 4.33.3 VBY-825 Mechanism of Action
  - 4.33.4 VBY-825 Licensing/Collaboration Companies
  - 4.33.5 VBY-825 Clinical Trials
- 4.34 Tetrodotoxin Drug Details
  - 4.34.1 Tetrodotoxin Current Status
  - 4.34.2 Tetrodotoxin Drug Overview
  - 4.34.3 Tetrodotoxin Mechanism of Action
  - 4.34.4 Tetrodotoxin Licensing/Collaboration Companies
  - 4.34.5 Tetrodotoxin Clinical Trials
- 4.35 zucapsaicin Drug Details
  - 4.35.1 zucapsaicin Current Status
  - 4.35.2 zucapsaicin Drug Overview
  - 4.35.3 zucapsaicin Mechanism of Action
  - 4.35.4 zucapsaicin Licensing/Collaboration Companies
  - 4.35.5 zucapsaicin Clinical Trials

## **5. LATEST CANCER PAIN PIPELINE NEWS AND DEALS**

## **6. APPENDIX**

- 6.1 Our Databases and Reports
- 6.2 Research Methodolgy

## I would like to order

Product name: 2020 Cancer Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

Product link: <https://marketpublishers.com/r/20DC2A1DCA7BEN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/20DC2A1DCA7BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

